Following the landmark National Institute of Neurological Disorders and Stroke (NINDS) trial, which demonstrated improved long-term outcomes in patients treated with recombinant tissue plasminogen activator (tPA) for AIS, the US Food and Drug Administration (FDA) approved tPA for AIS in 1996 [1,2]. Here, PLAT is linked to androgen insensitivity syndrome.